Trial site
London
London, Ontario N6A 4L6, CanadaNot linked to an institution yet
- 8running trials
- 1closed trial
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 34 trials
- Phase 13 trials
- Phase 22 trials
- Status
- Active, not recruiting6 trials
- Recruiting2 trials
- Completed1 trial
- Lead sponsor
- GlaxoSmithKline7 trials
- Tesaro, Inc.2 trials
Running trials
Active, not recruiting
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234· Phase 1· GlaxoSmithKline· Source
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698· Phase 2· GlaxoSmithKline· Source
Contact: Mohammad Qasim Khan (principal investigator)
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323· Phase 3· GlaxoSmithKline· Source
Contact: Hana Serajeddini (principal investigator)
Active, not recruiting
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
NCT04091126· Phase 1· GlaxoSmithKline· Source
Active, not recruiting
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error